Ironwood Pharma (IRWD) Misses Q2 EPS by 6c, Revs Miss

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. WDC
3. DECK
4. BYD
5. SPOT
6. WCN
7. FIX
8. BE
9. AXP
10. NDAQ

Go back to Ironwood Pharma (IRWD) Misses Q2 EPS by 6c, Revs Miss

Ironwood Pharmaceuticals Provides Second Quarter 2017 Investor Update

August 3, 2017 4:01 PM EDT

LINZESS® (linaclotide) expanded IBS-C/CIC branded prescription market leadership in 2Q 2017 with 19% growth in volume year-over-year and $168 million in U.S. net sales

Positive IW-3718 Phase IIb top-line data in uncontrolled GERD support advancement into Phase III

Multiple additional catalysts expected in 2H 2017, including DUZALLO® (lesinurad and allopurinol) approval and launch, three mid-stage data readouts and four mid- to late-stage trial initiations

CAMBRIDGE, Mass.--(BUSINESS WIRE)--... More